Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial
Sarah Baker, Benjamin Mou, W. Jiang, M Liu, Alanah Bergman, Devin Schellenberg, Abraham Alexander, Hannah Carolan, Siavash Atrchian, Tanya Berrang, Andrew Bang, N. Chng, Quinn Matthews, Scott Tyldesley, Robert Olson
Topics & Concepts
MedicineSABR volatility modelInternal medicineInterquartile rangeHazard ratioOncologyPopulationRadiation therapyProportional hazards modelConfidence intervalEnvironmental healthStochastic volatilityFinancial economicsEconomicsVolatility (finance)Brain Metastases and TreatmentLung Cancer Research StudiesLung Cancer Diagnosis and Treatment